... meaning that MRNS' drug will prove safer for long term usage than SAGE's, which has steroid-induced side effects. Ganaxolone is an analogue of their drug (allopregnanolone) which can now be used orally and which does NOT metabolize into an active steroid. This, in the end, will make our drug the preferred one in the marketplace. And I believe that these GABAa agonists will be used in treating many CNS-related conditions in addition to epilepsy and Fragile X syndrome.... Depression, PTSD, etc. Multi--billion $$$ indications.
It's all about risk/reward. We have a competing product to SAGE's, in oral form, that doesn't metabolize into an active steroid--unlike SAGE's drug--at 1/10 the market cap...
I agree.... it's the beginning of sector rotation. And in a couple of months, after biotechs have recovered, Kramer will tell everyone to start buying biotechs again since things are better now. That's our sell signal lol
-I know nothing about BDSI, sorry.
My gut feeling is we are about to start a several week or months' run in Biotech. We are at the beginning.
I own MRNS, IDRA, and AVXL, and dipped my toe into EDGE today.
Yep, maybe next week will be our true breakout week.
Painted the tape again to fade the close, as usual. Bullish sign, actually.
I agree. Assuming that institutions and insiders aren't selling or playing games, there're only maybe 2 mil free shares available. So it can move fast, especially when people realize that we have a safer drug than SAGE's at 1/10 the stock price.
Very true, entering and exiting are both difficult with the low float. It's hard to get bids filled, and you're always chasing. When I bought in, I wound up mostly placing market orders and let the chips fall where they may. On the other hand, if one needs or wants to sell, obviously it would be beneficial to do it on a high volume day. We'll get plenty of those this summer!
I agree, MRNS is angry. Nonetheless, it's bullish. The researchers want to be the first to announce results. They wouldn't care as much if results were poor. Second, I disagree with you regarding Dr. Kooy of Belguim giving the presentation instead of Dr. Hagerman of the USA. He proposed and invented the theory of GABA receptor dysfunction in Fragile X syndrome. It's his life's work. As prestigious as Dr Hagerman is, this change is also a bullish indicator.
Your 5/13 day EMA thing hasn't really worked for biotechs recently, which includes IDRA and MRNS. I doubt the MACD will either. MM's just running them up and down.
Thanks for the update. I didn't catch that the completion date for FX has been pushed back. I don't think that they're crunching the numbers....it doesn't take 3 months to do that.
That means that the FX trial, Adult Focal, and Infantile results will be right after one another...within a few months. Wow, what a wild ride that might be. In one way I'm relieved.. The 100K share dump last week and the weakness this week wasn't related to imminent (and presumably poor) FX results.
Look at CPXX -- pain for 2 straight years, then boom, up 400%. That's the way it goes sometimes.
Well, VA, I'm still here. Fortunately, I have a longterm timeline. We've had some violent moves, and they sure are testing our mettle. I'm staying because of the potential of this drug and the low market cap.
Finally, what the stock price does before the binary results that will occur over the next 6 months won't mean much in the end.
Just about all biotechs are going down after their pops.
To look at the optimistic side, at least CPXX continues to go up and is being rewarded after good trial results. The potential for reward is still there, so taking risk can still pay off in the end.
Can go either way irrespective of the market due to the tiny free float and and the nature of the institutional investors (non-public mostly biotech-specific niche hedge funds). T.A just isn't that reliable here. Just a couple of 100K purchases or dumps will throw every T.A. indicator out of whack.